AlphAIalphai — Financial news for AI agents
SEC EDGARAUG 32 min read$KMTS

Ford Alfred J Jr sold $643K of KMTS

Ford Alfred J Jr (Chief Commercial Officer) sold 27,632 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at an average of $23.25 ($22.61–$23.90, $0.64M total) across 3 trades over 2026-07-30 to 2026-08-03.

Original reporting
SEC EDGAR · Ford Alfred J Jr
Published Aug 3, 2026, 11:32 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 3, 2026, 11:33 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefInsider activity
Primary signal
$KMTS
Neutral
medium confidence
Mentioned
$KMTS
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

The newest disclosed fact is the CCO’s open-market sale details (shares, price range, total value, and post-transaction holdings).

02

Market read

Traders may monitor for follow-on insider activity, but there is no accompanying guidance, trial, deal, or regulatory development in the text.

03

What to watch

The trades span multiple days and explicitly state no pre-arranged 10b5-1 plan, which can increase scrutiny, but the article provides no context on motivations or future intent.

Relevance 5/10Novelty 5/10Timing: Filed 2026-08-03, covering sales from 2026-07-30 to 2026-08-03.

Background

The article is an SEC Form 4 insider transaction filing for Keystra Medical Technologies, Ltd. (KMTS).

Company-level read

Ticker impact

$KMTSNeutralMedium confidence
Context

Form 4 shows CCO Alfred J. Ford Jr sold 27,632 KMTS shares in open-market trades for about $642.5K, with no 10b5-1 plan.

Expected impact

Likely limited, short-lived impact unless follow-on selling or unusual volume emerges.

Evidence & confidence

The filing is a primary-source Form 4 and quantifies the sale size and timing, but it does not include new operational, financial, or regulatory information.

Market effects

Sector

Minimal, as the disclosure is company-specific and does not indicate sector-wide regulatory or demand changes.

Regional

Minimal, no macro or cross-regional catalyst is described.

Global

Minimal, no international transaction or global regulatory action is mentioned.

Counterpoint

What could challenge this read

Insider sales can be driven by diversification or tax planning, so the signal may be weaker than the headline implies.

Key entities

  • issuer
    KMTS

    Keystra Medical Technologies, Ltd., the company whose insider transaction is disclosed.

  • insider
    Alfred J. Ford Jr

    Chief Commercial Officer who sold 27,632 shares in open-market transactions.

Read at source← All news

Related articles

JUL 16
$KMTSMedAI 8/10

Kestra Medical Technologies Q4 Earnings Call Highlights

Kestra Medical Technologies (NASDAQ:KMTS) reported a Q4 GAAP net loss of $38.8 million and adjusted EBITDA loss of $26.7 million. CFO Vaseem Mahboob said gross margin should rise steadily and reiterated confidence in gross margins above 70% over the next few years. The company guided FY2027 revenue to $137 million, up 44% from FY2026, and added a $200 million term loan facility.

yahoo.com6 min
JUL 15
$KMTSMed

Kestra Medical Technologies Ltd (KMTS) Q4 2026 Earnings Call Highlights: Record Revenue

Kestra Medical Technologies (KMTS) reported Q4 2026 call highlights. CFO Vaseem Mahboob said fiscal 2027 guidance targets $137 million revenue, driven by prescription volume growth, in-network mix, revenue cycle management improvements, and field expansion, with 44% growth. CEO Brian Webster discussed WCD guideline support, share gains, adding ~40 reps, and refinancing to cut cost of capital by 24% while keeping an M&A option open.

yahoo.com4 min
JUL 15
$KMTSMed

Kestra Medical (KMTS) Q4 2026 Earnings Call Transcript

Kestra Medical (KMTS) discussed its FY26 results on an earnings call. Revenue was $95 million for the year, up 59% from FY25, and $28.6 million in Q4, up 66% year over year. Gross margin rose to 51.4% for FY26 (up about 11 pts). The company reported 6.3k prescriptions and expanding sales territories to about 130.

yahoo.com7 min
JUL 14
$KMTSMedAI 8/10

Kestra Medical Technologies Secures Up to $200 Million of Non-Dilutive Financing

Kestra Medical Technologies (Nasdaq: KMTS) announced a five-year, non-dilutive term loan facility managed by Pharmakon Advisors. It includes $75M funded at closing (used to retire a $45M loan plus fees), $25M available through July 2027, $50M through June 2028 subject to $150M trailing revenue, and a $50M acquisition tranche. Interest is SOFR plus 5.5% with a 3.25% floor; Kestra reported $262M cash/investments as of Apr. 30, 2026.

manilatimes.net4 min